Abstracts

PATTERNS OF ADHERENCE IN BICTEGRAVIR- AND DOLUTEGRAVIR-BASED REGIMENS

Regimen complexity can adversely affect adherence, leading to virologic failure. It is unknown whether this occurs with regimens that contain the second-generation integrase inhibitors (INSTIs), bictegravir and dolutegravir, both of which are recommended in the current DHHS Guidelines. EMR, prescription and dispensing data for 2,217 patients initiating BIC/FTC/TAF, DTG/ABC/3TC, DTG+TDF/FTC, or DTG+TAF/FTC between Aug 2013…

ONCE-DAILY ETRAVIRINE/RALTEGRAVIR (400/800 MG) AS MAINTENANCE REGIMEN

The ANRS163-ETRAL study showed 99.4% of virological success rate for etravirine/raltegravir (200/400 mg) twice-daily (ETR/RAL BID) dual therapy in suppressed HIV-infected patients older than 45 years [Katlama C, et al., J Antimicrob Chemother, 2019]. To simplify this regimen, we aimed to assess the efficacy of etravirine/raltegravir (400/800 mg) given once-daily (ETR/RAL QD). Patients with plasma viral load…